We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'
AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'View Video
GraniteShares making investing in US tech stock giants easier with innovative FAANG ETP
GraniteShares making investing in US tech stock giants easier with innovative FAANG ETPView Video

Latest Share Chat

Cambridge university aims for autumn trials of coronavirus vaccine after UK funding

Wed, 26th Aug 2020 00:01

LONDON, Aug 26 (Reuters) - The University of Cambridge is
aiming to start clinical trials of its possible coronavirus
vaccine in the autumn after it received 1.9 million pounds ($2.5
million) in funding from the British government, the university
said on Wednesday.

The scientists behind the vaccine said their approach, which
uses genetic sequences of all known coronaviruses to hone the
immune response, could help avoid the adverse effects of a
hyper-inflammatory immune response.

"We're looking for chinks in its armour, crucial pieces of
the virus that we can use to construct the vaccine to direct the
immune response in the right direction," Jonathan Heeney, head
of the Laboratory of Viral Zoonotics at the University of
Cambridge, said.

"Ultimately we aim to make a vaccine that will not only
protect from SARS-CoV-2, but also other related coronaviruses
that may spill over from animals to humans."

No vaccine against the SARS-CoV-2 coronavirus which causes
COVID-19 has yet been proven clinically effective, though 30
that use a range of technologies are in human trials already.

The Cambridge candidate, DIOS-CoVax2, is DNA based.
Computer-generated antigen structures are encoded by synthetic
genes, which can then re-programme the body's immune system to
produce antibodies against the coronavirus.

This DNA vector method has been shown to be safe and
effective at stimulating an immune response in other pathogens
in early stage trials, the university said.

Although it is operating at a later timetable than some
other vaccine candidates, the DIOS-CoVax2 shot would not need to
be stored at cold temperatures and could be delivered without
needles, possibly making the widespread distribution of the
vaccine easier.

"This could be a major breakthrough in being able to give a
future vaccine to huge numbers of people across the world," said
Saul Faust, Director of the NIHR Southampton Clinical Research
Facility.

($1 = 0.7611 pounds)

(Reporting by Alistair Smout; Editing by Mark Potter)

More News

Numis plans to open Dublin office after record interim results

Numis plans to open Dublin office after record interim results

Today 13:38

UPDATE 1-Bank of England does not see COVID bankruptcy wave - Haldane

(Adds Haldane comments on inflation, background)LONDON, May 7 (Reuters) - The Bank of England does not expect to see a wave of bankruptcies among British firms when the government ends its coronavirus emergency support for the economy, BoE Chief E...

Today 13:34

Custodian REIT declares fifth interim dividend for 2021

(Sharecast News) - UK-focussed property investment company Custodian REIT confirmed a fifth interim dividend per share for the financial year ended 31 March on Friday.

Today 13:33

England R rate 0.8-1.0, epidemic might be shrinking less slowly

LONDON, May 7 (Reuters) - The estimated reproduction "R" rate in England has dipped to between 0.8 and 1, Britain's health ministry said on Friday, but the epidemic might be shrinking a little less quickly than before.An R value between 0.8 and 1....

Today 13:30

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.